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ABST RACT

We present a literature review which summarizes the data supporting
one of the alternative perspectives on the effect of alcohol consumption
on cognitive aging – the possible positive effect of low to moderate
drinking. Some of the main theories about aging, the mechanisms of
brain aging, and the pathogenesis of cognitive decline and dementia are
briefly described. In this context, the putative mechanisms of the
protective action of non-alcoholic components in alcoholic beverages or
low doses of ethanol against oxidative stress, inflammation,
mitochondrial dysfunction, brain insulin resistance, and production of
amyloid-β peptides are presented. The review article does not favor the
data selected and highlighted, but it aims at inspiring more interest and
further research on the topic.

Introduction
Aging is defined as an age-related progressive inability
of the body's internal and genetic mechanisms to defend,
maintain and repair themselves in order to continue to
function effectively [1]. As a result, many harmful changes
accumulate in the cells and tissues with age. The cell loss
and dysfunction that occur during normal aging lead to
impaired
organ
functioning
and
inter-organ
communication in the physiological systems and the body
as a whole. The declining biological functions decrease
resistance and adaptability, while the risk of diseases and
death increases [2,3].
The outlined life perspective logically raises two
existential questions: 1) whether the inevitable can be
delayed and 2) how to live the allotted time. From a
scientific point of view, these issues belong to the field of
the so-called Anti-Aging Medicine [1]. Numerous studies
have focused on different means of slowing down aging
and prolonging life. There have been many attempts to find
optimal diets and lifestyles that contribute to healthy
longevity. Inevitably, when it comes to nutrition, the
question of alcohol consumption arises [4]. This literature
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review focuses on the currently available data about the
beneficial effects of moderate alcohol drinking as an
important component of "successful" aging – cognitive
integrity. Understanding the mechanisms of the potentially
beneficial effects of moderate alcohol use implies
knowledge of normal brain aging.

Discussions
The process of aging
The research on age-related physiological changes and
their causes reveals aging as an extremely complex and
multifactorial process. There are over 300 theories about
aging, which should not be considered as mutually
exclusive, but rather complementary in an attempt to
explain the signs of the normal aging process [5,6].
According to the theory of free radicals, aging is the
result of the accumulation of endogenous reactive oxygen
species (ROS), and the associated oxidative stress [7]. The
mitochondrial theory of aging focuses on ROS-induced
mitochondrial DNA damage [8,9]. The well-known link
between inflammation and oxidative stress relates the
inflammatory hypothesis of aging to the free radical theory
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of aging [10]. Overproduction or the uncontrolled release
of reactive oxygen and nitrogen species and the reduced
capacity of endogenous antioxidant mechanisms are the
major causative factors of tissue inflammation. The
dysfunction in the regulatory pathways, occurring with
age, upsets the balance between anti- and proinflammatory
agents in favor of the latter, and maintains chronic
inflammation. The immune theory of aging suggests that a
network of cellular and molecular mechanisms, including
DNA repair systems, enzymatic and non-enzymatic
antioxidant systems, the production of heat-shock proteins,
etc. controls the aging process indirectly [11]. All these
mechanisms limit the negative effects of various physical,
chemical, biological, etc. stressors and increase life
expectancy.
In addition, the neuroendocrine-immune hypothesis
draws attention to the interaction between the nervous,
endocrine, and immune systems including different
neurotransmitters, neuropeptides, and cytokines [8].
According to the waste accumulation theory, the inability
to effectively remove the non-degradable by-products of
metabolism with subsequent accumulation of metabolic
wastes contributes to cell aging [6]. Examples of
extracellular deposits are cholesterol-containing plaques in
blood vessels, and protein polymers, such as β-amyloid, in
the central nervous system (CNS) (amyloid plaques). In
summary, the current theories on aging demonstrate that
different processes contribute to aging; they interact and
simultaneously work at different levels of functional
organization [12].
Brain aging and cognitive functions
As people advance in age, the efficiency of brain
functions, in particular the cognitive ones, are negatively
altered. By definition, cognitive functions encompass those
mental processes through which knowledge is acquired and
the understanding of the world occurs – perception,
attention, memorization, reasoning, evaluation, problemsolving, decision making, creativity, and speech [13,14].
Observations show that the age-related decline in cognitive
functions in healthy people begins in the third decade of
life and continues throughout life. [4].
Aging is an irreversible process that depends on
genetic and environmental factors and involves
complicated metabolic and molecular mechanisms. The
cardiometabolic mechanism reveals that the vascular
pathology associated with obesity, type 2 diabetes, and the
metabolic syndrome, contributes to cognitive decline and
dementia in adults. However, the problems are not limited
to reduced brain perfusion. An interesting aspect of the
metabolic mechanisms is the defective insulin sensitivity
and signaling in the brain [15-17]. Insulin regulates the
energy metabolism of neurons, as well as their
differentiation, growth, survival, synaptic plasticity, and
6

neurotransmission. In the hippocampus, it contributes to
the long-term potentiation, thus affecting learning and
memory. Therefore, brain insulin resistance will disturb the
above-mentioned processes. Recently, researchers have
proposed the phrase "type 3 diabetes" for Alzheimer's
disease, because of the shared molecular and cellular
characteristics between insulin resistance and cognitive
decline in the elderly [18].
Vitamin D is another pleiotropic regulator, which is
involved in the neurodegenerative processes that occur
with aging. Vitamin D deficiency, which is common in
elderly people, is considered a risk factor for cognitive
decline and dementia [19-21]. Vitamin D plays a
neurotrophic and neuroprotective role by stimulating the
synthesis of neurotrophic agents such as nerve growth
factor
and neurotrophins in
astrocytes and
oligodendrocytes [22,23]; it regulates calcium
homeostasis in the brain [24,25], it modulates brain
neurotransmitters, and displays anti-inflammatory
activity by suppressing the pro-inflammatory cytokines in
the brain [26,27]. Moreover, vitamin D has an antioxidant
activity and inhibits the generation of ROS, lipid
peroxidation, and the inactivation of some antioxidant
enzymes [28].
The free radical theory of aging postulates that free
radical reactions contribute to aging. The brain is one of the
most metabolically active organs, where a delicate balance
is maintained between the mechanisms of production of
free radicals and the mechanisms of brain defense [29]. The
moderate production of ROS by mitochondria, described
as a physiological level of oxidative stress, is known to upregulate the program of mitochondrial biogenesis and the
antioxidant capacity of the brain, and thus works in favor
of brain protection. However, the accumulated oxidative
damage and the deterioration of the mitochondrial function
in the aging brain causes changes in cellular architecture.
Therefore, it is logical to assume that the uncontrolled
production of free radicals is a major factor in the loss of
neuronal homeostasis and the development of
neurodegenerative diseases [30].
Neuroinflammatory processes also contribute to brain
aging. Experimental data from animal models with
Alzheimer's disease and Parkinson's disease indicate that
systemic inflammation initiates an exacerbated immune
response in the CNS through the local innate immune
system, the microglial cells. Microglia become easily
susceptible to secondary inflammatory stimulation, which
can elicit an excessive inflammatory response [31]. The
sustained activation of microglia changes their functions
and induces the increased secretion of proinflammatory
cytokines and neurotoxic factors that contribute to the
systemic inflammation and the progression of
neurodegenerative diseases [32, 33].
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Sometimes, it is difficult to distinguish between the
normal changes in the aging brain and the incipient
neurodegenerative processes. Alterations in brain tissue
can precede the occurrence of clinical signs and/or
neuropathological lesions by years and can be detected in
elderly individuals who do not show cognitive decline
[34].
Therefore, a lot of effort has been invested in
elucidating the pathogenesis of degenerative brain
diseases and identifying reliable biomarkers for the
diagnosis of preclinical and prodromal stages of
dementia. Studies over the past 30 years have shown that
the pathogenesis of Alzheimer's disease involves a
plethora of events related to the impaired production,
degradation, and clearance of amyloid-β protein (Aβ).
The initial events of this plethora include the
overproduction of amyloid-β precursor protein (AβPP)
caused by rare mutations in the AβPP, PSEN1 or PSEN2
genes, malfunctioning of Aβ-degrading proteases, and
impaired Aβ clearance from the brain due to inefficient
transport mechanisms [6,35].
The imbalance between production and clearance
leads to an accumulation of excessive amounts of Aβ,
which are thought to initiate a sequence of pathological
changes such as loss of synapses and neurons, impaired
glucose uptake, oxidative damage, the impairment of brain
energy metabolism, tau hyperphosphorylation, and the
formation of neurofibrillary tangles, amyloid plaque
deposition and, ultimately, neurodegeneration. This
complex cascade of pathological events continues in the
course of the development of Alzheimer's disease, and
leads to the accumulation of structural and functional
damage to the brain, causing the key symptoms of the
disease [35]. In this context, in addition to the established
diagnostic biomarkers of Alzheimer's disease –
cerebrospinal fluid Aβ42, total tau (tTau) and
phosphorylated tau181 (pTau181) [36], the possibilities of
detecting soluble forms of the amyloid precursor protein
(APP) in cerebrospinal fluid and blood are also evaluated
[37].
Brain-imaging techniques (PET, MRI) also present a
high potential for the structural-topographic assessment of
pathological changes [4]. Recently, views on the
pathogenesis of Alzheimer's disease have become more
complex with the established role of oxidative damage
associated with an increased production of ROS, the loss
of mitochondrial function, altered metal homeostasis, and
decreased antioxidant protection, which may affect the
production
and
accumulation
of
Aβ
and
hyperphosphorylated Tau protein. The latter can become
components of a vicious circle that can exacerbate
mitochondrial dysfunction and ROS production [38].

The prevention and delay of cognitive aging through
nutritional (food and drink) strategies
To find the "fountain of youth" has been the
everlasting dream of humankind. Through hygiene,
vaccines, antibiotics, insulin, and high-tech interventions,
advanced medicine has led to increased life expectancy
over the last century. This is currently a global trend.
According to the data from the European Commission
and Eurostat, by the year 2060, the elderly population
(aged 65 and above) is expected to grow from 17.4% to
almost 30% [4], while for the population over the age of
80, the increase is expected to increase fivefold [39]. This
inevitably raises the question of the quality of life of this
growing share of the human population, which largely
depends on full cognition. As part of the efforts of "antiaging" medicine, optimal means, interventions, and
approaches for slowing down cognitive aging and the
prevention of neurodegenerative diseases are sought [40].
However, it must be acknowledged that preventive
methods have a limited capacity and that there are
currently no means of stopping or reversing the aging
process in humans. This gives rise to tendencies to
develop complex strategies for maintaining cognitive
health.
Preclinical and clinical studies on healthy individuals
or people in the early stages of cognitive decline have
shown the potential of nutrition to exert a beneficial effect
on cognitive functions [4,41]. It is well known, not only
in the scientific community, that long-term adherence to
the Mediterranean diet (rich in fruits, vegetables, nuts,
olive oil, moderately saturated with fish and poorer in red
meat) is associated with better cognition in adults and
reduced risk of dementia or Alzheimer's disease
[38,42,43]. Moderate drinking of mainly red wine is
commonly reported as a component of the Mediterranean
diet. Wine is not the only alcoholic beverage that is
present on the table of different nations. This increases
the scientific interest in the potential health benefits
(including mental) of moderate alcohol consumption
worldwide [44].
The interest is not only global, but also ancient. The
Sumerian cuneiform and Egyptian papyri, dating back to
2200 BC, contain prescriptions for wine-based medicines
[38,45]. In ancient Greece, Hippocrates (460-370 BC)
considered wine to be part of a healthy diet and even
prescribed it as a medicine for some diseases [45].
Speaking of ancient Greece, it is interesting to quote the
poet Ebulus, who presents views on moderate wine
consumption in one of his plays: "For moderation, three
kiliks (three cups) are placed: one for health, the first to be
emptied, the second for love and pleasure, and the third for
sleep." [46]. Historical data about the suitability of wine for
the treatment of dementia, in particular, can be found in the
7
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first printed book on wine, written by the physician and
theologian Arnaldus de Villa Nova in the 14th century [47].
Тhe views and practices of ancient and medieval
physicians do not seem unfounded, because studies and
literature reviews from the late 20th and early 21st
centuries provide evidence that moderate alcohol use in
middle age and older age can be considered, albeit
cautiously, protective against dementia in old age. An
analysis of the results of the epidemiological studies
published between 1998 and 2008 shows that light to
moderate drinking is associated with a 38% lower risk of
dementia and a 32% lower risk of developing Alzheimer's
disease [48,49].
Similar conclusions were reached by the meta-analysis
of 15 studies, which revealed that light to moderate alcohol
consumption in adulthood reduces the risk of dementia by
47% compared to abstainers. Solfrizzi and co-authors
monitored alcoholic patients with mild cognitive
dysfunction, which is considered an early symptom of
Alzheimer's disease. According to the observation,
consuming up to 15g of alcohol per day reduces the rate of
progression to dementia by approximately 85% [50].
Impressive in its scale is the prospective study by Zhang
and co-workers, the results of which have been published
recently [51]. A nationally representative sample of 1,887
participants (with a mean age of 61.8 years) assessed the
association of alcohol consumption and age-related decline
in cognitive function, using multiple cognitive
measurements, which have been carried out for 12 years.
The data show that low to moderate alcohol use is
associated with better general cognition and better results
in specific cognitive domains – word recall, mental status,
and vocabulary. Low to moderate drinking is also
associated with a slower rate of cognitive decline in these
domains.
The findings are consistent with another study
conducted among people living in a community (with a
mean age of 73.2 years), where regular moderate alcohol
consumption was associated with better cognitive function
as compared to abstainers. Some of the prospective
population-based studies have found a J-shaped, others a
U-shaped curve in the link between alcohol consumption
and the risk of cognitive dysfunction and dementia, which
is considered evidence for the potential beneficial effects
of moderate alcohol consumption [38,41,51-56]. This
includes the cumulative effects of moderate alcohol
consumption in youth and middle age – according to the
data summarized by Stockley in 2015. Compared to
abstainers, people who regularly consume moderate
amounts of alcohol display higher scores in terms of
attention stability, information processing speed,
immediate or delayed word reproduction, recognition
memory, working memory, and other cognitive
dimensions.
The topic of the type of alcohol consumed is worth
considering, along with the potentially beneficial effects of
8

moderate alcohol consumption. Moussa et al. (2015) report
that long-term moderate alcohol use does neither
exacerbate nor accelerate the natural course of age-related
decline in cognitive function [53]. Similar conclusions are
drawn by Huang et al. (2002) [54] who, in a prospective
study of 402 residents of the Kungsholmen district in
Stockholm, aged 75 and above, found that light to
moderate alcohol consumption (wine, beer, or liquor) was
associated with a reduced incidence of dementia and
Alzheimer's disease. They hypothesize that this association
may reflect a potentially protective effect of light to
moderate alcohol consumption on the development of
dementia and Alzheimer's disease; this effect may be
attributed to alcohol per se, and cannot be related to the
type of alcoholic beverages consumed.
However, based on the data from other publications, it
can be assumed that "In vino veritas. i.e. In wine, there is
truth". Neafsey and Collins, assessing the correlation
between alcohol consumption and age-related decline in
cognitive function, have found evidence for a beneficial
effect of moderate alcohol consumption [55]. The analysis
(based on the data from 14 countries) showed that wine has
a more pronounced protective effect than beer and hard
alcohol.
Another prospective study on 2,613 men and women
aimed at assessing the association between alcohol
consumption (total and different types of beverages) and
cognitive decline in middle age (assuming that slowing the
rate of cognitive decline leads to the preservation of
cognitive functioning in old age) [56]. The global cognitive
function and specific domains such as memory, speed, and
flexibility were assessed twice at 5-year intervals. It has
been found that moderate intake of red wine is associated
with the smallest decline in global cognitive function,
memory, and cognitive flexibility (especially in women),
while moderate use of other alcoholic beverages (more
common in men) does not correlate with the rate of
cognitive decline.
These findings support the assumption that the nonalcoholic substances in red wine are most likely
responsible for the cognitive preserving effect (see the next
section). The beneficial effect of wine is also confirmed by
the results of a study including 980 individuals aged 65 and
above without dementia at baseline [57]. After 4 years of
follow-up, 260 people developed dementia, (199 of them
developed Alzheimer's disease). The analysis of alcohol
use and habits of the persons led the authors to the
conclusion that the consumption of up to three servings of
wine daily (33 g of alcohol) is associated with a lower risk
of developing Alzheimer's disease. According to a study
assessing the association between average alcoholic intake
and cognitive performance in 15,807 patients, daily alcohol
consumption of less than 40 g for women and 80 g or less
for men is associated with a decreased probability of
cognitive impairment [58].
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Table 1. Excerpts from the cited reference list regarding drinking categories/doses and beneficial/not
harmful/harmful effects of alcohol.
Reference

Drinking categories and doses

Findings

Huang et al.,
Ref № [54]

Nondrinker: <1 unit per week (1 standard unit
= 8 g ethanol).

Light to moderate alcohol consumption is
associated with a decreased incidence of
dementia and Alzheimer’s disease.

Light to moderate drinker: 1–21 units per week
for men, or 1–14 units per week for women.
Excessive drinker: >21 units per week for men,
or >14 units per week for women.
Solfrizzi et al.,
Ref № [50]

No alcohol intake.
≤1 drink per day (approximately 15 g of
alcohol).
1 or more drinks but ≤2 drinks per day.

Moussa et al.,
Ref № [53]

>2 drinks per day.
Light alcohol consumption: 1–8 drinks per
month (not exceeding two drinks per week).
Moderate alcohol consumption: 7–21 drinks
per week (not exceeding three drinks per day).

Patients with mild cognitive impairment who
are moderate drinkers (who consumed 1.0 to
14.9 g of alcohol per day, derived mostly
from wine) have a lower rate of progression
to dementia than the non-drinkers.
There is no evidence to support the idea that
long-term moderate alcohol consumption in
older adults exacerbates age-related cognitive
decline.

Standard drink sizes: 12 oz glass (beer), 5 oz
glass (wine), 1.5 oz glass (hard liquor).
Kim et al.,
Ref № [69]

No drinking.
Mild drinking: <1 standard drink per week
(<10 g of pure alcohol per week).
Moderate drinking: 1–13 standard drinks per
week (10–130 of pure alcohol per week).

Moderate lifetime alcohol intake is
associated with lower cerebral Aβ deposition
compared to a lifetime history of not drinking
in middle- and old-aged individuals with
neither dementia nor alcohol-related
disorders.

Unsafe drinking: 14+ standard drinks per week
(≥140 g of pure alcohol per week).
Siddiquee et al., Very light drinkers: <14 g ethanol per day.
Ref № [97]
Light drinkers: 14–23 g ethanol per day.
Moderate drinkers: >23–46 g ethanol per day.
Zhang et al.,
Ref № [51]

Heavy drinkers: >46 g ethanol per day.
Low to moderate drinkers: <8 drinks per week
for women and <15 drinks per week for men.
Heavy drinkers: ≥8 drinks per week for women
and ≥15 drinks per week for men.

Reale et al.,
Ref № [38]

The results obtained do not suggest any
beneficial or adverse relationship between
the alcohol consumption levels and cognitive
functioning in current elderly drinkers over
that in never-drinkers.
Low to moderate drinking is associated with
a consistently high cognitive function
trajectory and a lower rate of cognitive
decline.

Consumption of alcohol between 1 and 14 units
per week (1 unit = 10 mL or 8 g pure alcohol).

There is no evidence that the consumption of
alcohol between 1 and 14 units per week
increases the risk of dementia.

Consumption of alcohol >14 units per week.

Consumption of alcohol >14 units per week
linearly increases the risk of dementia with
age.

Biological mechanisms of the potential protective effect
of alcoholic beverages on cognitive aging and
dementia
Although there is evidence that the moderate
consumption of any type of alcoholic beverage may have a

protective effect on cognitive aging, wine is particularly
suitable for discussing the biological mechanisms of this
effect due to its rich composition of biologically active
substances. More than 500 compounds have been identified
in the fruit and wine of Vitis vinifera (grapevine) [41]. Wine
9
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contains alcohol, the largest amount being ethanol. The
concentration of ethanol in table wines usually varies
between 8 and 15 volume percent [59]. The main
difference between wine and other alcoholic beverages is
that wine contains phenolic compounds similar to those
found in fruits, vegetables, and tea, the consumption of
which is associated with a lower incidence of mild
cognitive dysfunction, dementia, and other cerebrovascular
neurodegenerative diseases. Wine contains two main
classes of phenolic compounds: flavonoids and nonflavonoids. Their relative content depends on several
factors such as the grape variety, climatic conditions, soil
type and the type of cultivation, wine production
technology, and wine aging. The main polyphenols in wine
are flavanols, flavonols, anthocyanins, and resveratrol.
Flavonoids
include
catechin,
epicatechin,
proanthocyanidins, flavones, and anthocyanins. Myricetin,
kaempferol, rutin, and quercetin are representatives of
flavonols. Delphinidin-3-glucoside, cyanidin-3-glucoside,
and malvidin-3-glucoside are the most common
anthocyanins in wine [38]. Some of the most important
flavonoids in wine are anthocyanins, flavanols (catechins
or flavan-3-ols), and flavonols (quercetin and myricetin);
the group also includes proanthocyanidins, dimers, and
oligomers of catechin and epicatechin and their gallic acid
esters. Non-flavonoids are different classes of compounds
that are substituted phenols. These include benzoic acid
derivatives (vanillic and gallic), benzaldehydes (vanillin
and syringe aldehyde), cinnamic acids (para-coumaric,
ferulic, caffeic), and cinnamon aldehydes (mustard
aldehyde) [60]. Non-phenolic compounds that contribute
to the antioxidant activity of wine are ascorbic acid and
sulfur dioxide [61]. Their natural content in wine is very
small, but they are often added in the winemaking process.
Sulfur dioxide inactivates the enzyme polyphenol oxidase
[62], which is responsible for the oxidation of phenolic
compounds, and thus contributes to the preservation of the
polyphenolic content and antioxidant activity of wine.
Resveratrol is an important compound in wine with
beneficial health effects. It is a natural phytoalexin that is
produced by some plants in response to damage [63].
Resveratrol belongs to the class of organic compounds
(stilbenes) and it is found in nature in two isoforms (i.e. cisand trans-), the trans isoform being biologically active.
Both isoforms are synthesized in the skin of grapes and
reach maximum concentration before ripening. Stilbene
synthase, the key enzyme in resveratrol biosynthesis, is
activated by exogenous factors such as stress, UV light,
chemical signals, and pathogens. Red grapes and red wine
contain about 3 to 10 times more resveratrol than white
ones, with an average trans-resveratrol content of 1.9 - 1.7
mg/L. According to our data, the highest polyphenolic
content is found in red wines (average of 567 ± 32 mg/L),
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followed by rosé (323 ± 84 mg/L) and white wines (281 ±
42 mg/L) [64]. The data from animal studies reveal that
phenolic compounds derived from grapes and wine are
absorbed, cross the blood-brain barrier, and accumulate in
the brain. Alcohol also plays an important role by
promoting their absorption and thus increasing their
bioavailability [65].
At present, it is difficult to state whether the possible
health benefits of wine are due to ethanol, its microcomponents, or to their synergistic effect. The complex
beneficial effect of phenolic compounds and ethanol on the
risk of cardiovascular and cerebrovascular diseases can be
associated with changes in the lipid profile, hemostasis,
and circulation [66]. In particular, an ethanol-induced
increase in HDL-cholesterol concentration (which is
inversely correlated with the risk of cardiovascular
disorder) has been reported. Light alcohol intake was
associated with an increased activity of tissue plasminogen
activator and decreased levels of plasma coagulation
factors such as fibrinogen, proconvertin, and von
Willebrand factor [67,68]. All these changes are associated
with a reduced risk of atherosclerosis, Alzheimer's disease,
and vascular dementia. The results obtained from human
studies reveal that moderate alcohol intake is protective
against vascular changes and atrophy in the brain, and
ischemic brain injury [69]. From the above data, it can be
concluded, that the main ingredients of wine will work
against dementia and in favor of the cognitive functions, by
counteracting atherosclerosis and protecting the brain from
ischemia.
As previously mentioned, brain aging and cognitive
decline are associated with oxidative stress, inflammation,
mitochondrial dysfunction, and brain insulin resistance. In
this regard, it is important to note that resveratrol can lower
ROS by down-regulating enzymes such as xanthine
oxidase, involved in the production of ROS and upregulating endogenous antioxidant enzymes (superoxide
dismutase, glutathione peroxidase, catalase, heme
oxygenase) [70,71]. Resveratrol can counteract the
production of mitochondrial ROS, resulting in increased
mitochondrial activity and bioenergetic efficiency. It is
considered that the inhibition of the ATP synthase by
resveratrol might play a significant role in the
pathophysiology of neurological disorders and aging [72].
Resveratrol modulates the activity of sirtuin 1 (SIRT1) and
thus the regulation of p53, a key protein involved in DNA
repair [73]. As a ligand of leukotriene A4 hydrolase,
resveratrol exhibits anti-inflammatory and antioxidant
activity [74]. The data оn the ability of its analogs to reduce
insulin resistance by improving energy homeostasis is
intriguing given the reduced insulin effectiveness,
accompanying brain aging [75]. Experiments have
demonstrated the neuroprotective effects of resveratrol, as
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well as the positive effects on cognitive functions, learning,
memory, and depressive state [76,77].
Red wine is a rich source of polyphenolic antioxidants
such as flavonols (quercetin) and flavonoids
(anthocyanins). Acting as an antioxidant, quercetin is
capable of effectively removing ROS [78] and may have a
protective effect in Alzheimer's disease and oxidative
stress-related neurodegenerative diseases. Quercetin exerts
neuroprotective effects against the toxic molecules by
modulating the mechanisms of cell death, increasing the
resistance of neurons to oxidative stress, inhibiting the
inducible nitric oxide synthase (iNOS), regulating
cyclooxygenase-2 (COX-2), and exerting the antiinflammatory activity [38]. The anthocyanins also exhibit
antioxidant and anti-inflammatory effects by inhibiting
inflammatory enzymes such as iNOS and COX-1 [79].
Oligonol, extracted from grape seeds and part of Vitis
vinifera must also be added to the polyphenol list with
antioxidant and anti-inflammatory effects [38, 80]. Since
oxidative stress and inflammation are linked to
neurodegeneration, the polyphenols in wine may exert
protective effects against neurodegenerative diseases.
What are the beneficial effects of wine ingredients in
the pathogenesis of Alzheimer's disease? This
neurodegenerative disease is characterized by amyloid-β
(Aβ) deposits and the accumulation of plaques in the brain.
Recently, Kim et al. (2020) have published some data that
moderate alcohol consumption throughout life is
associated with lower Aβ deposition in the brain as
compared to abstainers in middle-aged and elderly
individuals [69]. Aβ peptide is generated by proteolytic
cleavage of amyloid precursor protein (APP) by alpha,
beta, and gamma secretases. Unlike alpha-secretase, which
cleaves APP to the non-toxic amyloid alpha, toxic Aβ is
derived by the sequential action of beta and gamma
secretases. The most common isoforms that are produced
are Aβ40 and Aβ42. In experiments with transgenic mice
Tg2576 (an animal model of Alzheimer's disease), it was
found that the administration of red wine in doses
equivalent to two standard drinks leads to nonamyloidogenic processing of APP and thus prevents Aβ
production. The levels of amyloidogenic Aβ1-40 and Aβ142 in the neocortex and the hippocampus of mice were
decreased, while the alpha-secretase activity was increased
[81]. Resveratrol in red wine has been shown to have
beneficial effects on the pathogenesis of Alzheimer's
disease by affecting some molecular mechanisms of the
amyloid cascade. It lowers intracellular Aβ levels by
inhibiting the formation of Aβ fibrils and promoting
autophagic and lysosomal degradation of Aβ, it reduces
tau-phosphorylation and deposition, as well as Aβ-induced
ROS production [41,82]. Other polyphenols also
demonstrated beneficial effects on the pathogenesis of

Alzheimer's disease: quercetin inhibits Aβ synthesis, and
epigallocatechin-3-gallate modulates APP processing by
acting on the non-amyloidogenic α-secretase pathway and
counteracting Aβ-induced oxidative stress [38]. Aβ
aggregation has been recognized as a necessary condition
for Aβ-neurotoxicity. In vitro and animal studies have
shown that grape-seed derived polyphenolics (containing
mostly catechin and epicatechin) prevent Aβ
oligomerization and reduce the cognitive impairment in a
model with Alzheimer's disease [83].
Protein kinase C (PKC) is a family of protein kinase
enzymes, involved in signal transduction pathways; it is
also important in memory processes and learning [84].
PKC modulates APP processing and can reduce the
accumulation of pathogenic Aβ in the brain [85].
Resveratrol and epigallocatechin-3-gallate have been
reported to protect hippocampal neurons from Aβ-induced
toxicity by activating PKC [41].
Studies reveal changes in specific neurotransmitter
systems with normal aging and more deficits in dementia.
Severe loss of cholinergic neurons in the nucleus basalis is
a feature of Alzheimer's disease [86]. There is a reason to
believe that the impaired cholinergic neurotransmission
may also contribute to the formation of amyloid fibrillar
plaques. In this regard, it is worth noting that ethanol (in
low concentrations) can stimulate the release of
acetylcholine in the hippocampus with a positive effect on
cognitive functions [66]. This may explain the observation
that drinking small amounts of alcohol improves the
memory of the events that occurred before consumption in
healthy individuals [87]. There is also evidence that
acetylcholine levels may be positively affected by
catechins (epigallocatechin-3-gallate), which act as
acetylcholinesterase inhibitors [88]. The inhibition of
acetylcholinesterase contributes to the restoration of
cholinergic neurotransmission and appears to prevent the
aggregation of amyloid-β peptides and the formation of
amyloid fibrillar plaques [89].
A study on the effect of ethanol on the kinetics of βamyloid aggregation in vitro revealed that ethanol prevents
the formation of stable Aβ dimers in vitro, thus protecting
the cells maintained in culture [90]. The research of Bate
and Williams on the effects of ethanol on cultured cortical
and hippocampal neurons provides evidence that moderate
alcohol consumption prevents dementia in Alzheimer's
disease. Ethanol administered in physiologically relevant
concentrations of 0.02–0.08% protected neurons against
the synapse damage induced by Aβ42, a neurotoxin
responsible for memory defects occurring in Alzheimer's
disease [91].
While looking for approaches to counteract the
neurodegenerative processes in the brain associated with
oxidative damage as a result of high ROS production
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(generated, for example, by neurotoxic agents such as Aβ),
scientists have recently discovered the potential of
neurotrophins [92]. The brain-derived neurotrophic factor
(BDNF) is known to be a key regulator of neuronal
plasticity and development. Upon binding to its receptor,
BDNF activates a transduction-signaling pathway that is
common to the process of stimulating cell proliferation
and/or inhibiting the apoptosis cascade. Accordingly, it is
interesting to point out that moderate alcohol consumption
increases BDNF levels [93]. Regarding neurotrophins,
vitamin D is worth being mentioned again, because it
exerts its multifaceted neuroprotective effects by
regulating the synthesis of neurotrophins. Several studies
on humans presented data that alcohol consumption is
positively associated with vitamin D status and reduced
risk of vitamin D deficiency [94-96]. The mechanism by
which alcohol can affect serum vitamin D concentrations
is unclear at the moment, but the effects should not be
overlooked when talking about alcohol consumption,
neuroprotection, and cognitive well-being.

Highlights
✓ Prospective population-based studies have revealed a
J-shaped or a U-shaped curve in the link between
alcohol consumption and the risk of cognitive
dysfunction and dementia, which is considered
evidence for the potential beneficial effects of
moderate alcohol consumption.
✓ The more common opinion is that red wine has a more
pronounced protective effect than other alcoholic
beverages.
✓ The main ingredients of wine act against dementia and
in favor of the cognitive functions because phenolic
compounds and ethanol exhibit anti-inflammatory and
antioxidant activity, and reduce insulin resistance,
inhibit Aβ synthesis and lower the intracellular Aβ
levels, tau-phosphorylation, and amyloid plaque
deposition, thus counteracting the Aβ-induced
synaptic damage.

Conclusions
The data presented in this article reveal only a small
part of the discussion on the potentially beneficial effects
of moderate alcohol consumption on cognitive aging and
dementia, and the biological mechanisms of the beneficial
effects of alcohol and alcoholic beverages. Further research
is needed to confirm the data cited and to refute the other
common opinions (supported by reports in the scientific
literature) about the lack of beneficial effects of moderate
alcohol consumption on the cognitive functions in the
aging process [97-100].
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